Search for: "Courtenay Brinckerhoff" Results 21 - 40 of 92
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
9 Dec 2011, 9:45 pm by Patent Docs
The panel will include Courtenay Brinckerhoff of Foley & Lardner, Charles Doyle of Roche Molecular Systems, and Prof. [read post]
21 May 2016, 8:41 pm by Patent Docs
Patent and Trademark Office, Courtenay Brinckerhoff of Foley & Lardner, and Kevin Noonan of McDonnell Boehnen Hulbert & Berghoff LLP will probe deeply into the new examples published by the USPTO this month that show how claims for life science inventions should be examined by the agency for subject-matter patent eligibility. [read post]
5 Aug 2018, 9:52 pm by Patent Docs
Courtenay Brinckerhoff of Foley & Lardner LLP, Charles Chesney of Qualcomm Inc., and Roland McAndrews of Bookoff McAndrews PLLC will discuss potential pitfalls associated with U.S. provisional or CIP patent applications. [read post]
14 Nov 2011, 1:00 am by Stefanie Levine
The following analysis of the changes to 35 USC § 102 under the America Invents Act comes from Courtenay Brinckerhoff ,writer of PharmaPatents Blog and Partner at Foley & Lardner. [read post]
14 Nov 2011, 1:00 am by Stefanie Levine
The following analysis of the changes to 35 USC § 102 under the America Invents Act comes from Courtenay Brinckerhoff ,writer of PharmaPatents Blog and Partner at Foley & Lardner. [read post]
10 Aug 2012, 5:30 pm by Colin O'Keefe
Also in today’s roundup: Al Saikali breaking down the FTC’s $22.5 million fine against Google and Courtenay Brinckerhoff continuing her superb commentary on the America Invents Act. [read post]
26 Jan 2019, 8:38 pm by Patent Docs
Paul Hunter, Courtenay Brinckerhoff, and Daniel Rose of Foley & Lardner LLP discuss best practices for preparation and prosecution in view of the 2019 Revised Patent Subject Matter Eligibility Guidance, and address the following topics: • Key Takeaways and Evaluating the 2019 Revised Patent Subject Matter Eligibility Guidance • Section 101—Understanding Steps 2A and 2B • Prosecution Strategies for Obtaining Valuable Patents Under New Guidance •… [read post]
22 Jun 2009, 12:49 am
" The participants included Foley & Lardner attorneys Jonathan Spivey, Jon Dudas, Courtenay Brinckerhoff, and Sharon Barner, along with IBM's David Kappos, now indicated to be the nominee of Barack Obama for undersecretary at Commerce and Director of the USPTO. [read post]
20 Oct 2011, 2:00 am by Stefanie Levine
The following analysis of  the new 35 USC § 102(a)(2) provision in the Leahy-Smith America Invents Act eliminating the Hilmer doctrine and giving prior art effect to U.S. patent applications as of their foreign filing dates comes from Courtenay Brinckerhoff ,writer of PharmaPatents Blog and Partner at Foley & Lardner. [read post]
20 Oct 2011, 2:00 am by Stefanie Levine
The following analysis of  the new 35 USC § 102(a)(2) provision in the Leahy-Smith America Invents Act eliminating the Hilmer doctrine and giving prior art effect to U.S. patent applications as of their foreign filing dates comes from Courtenay Brinckerhoff ,writer of PharmaPatents Blog and Partner at Foley & Lardner. [read post]
1 Dec 2011, 5:38 pm by Colin O'Keefe
Instead, we have an interesting story coming out of Massachusetts from Donald Pinto and Courtney Brinckerhoff continues to do a good job tracking developments at the US Patent and Trademark Office. [read post]
24 Mar 2011, 2:35 am
Of late, Editor Courtenay Brinckerhoff has been discussing patent reform, human antibody claims, license agreements, and "definiteness. [read post]
4 Apr 2011, 8:36 pm by Lawrence B. Ebert
Or, as attorney Courtenay Brinckerhoff, a partner with the law firm Foley and Lardner, posed the question in a statement: "Can Myriad explain the difference between patenting isolated DNA and patenting a leaf that has fallen off of a tree? [read post]
2 Oct 2009, 8:21 am
" See Jon Dudas to Foley & Lardner DC office See also the IPBiz posts: Kappos and IBM in May 2009 discussing a panel including Foley & Lardner attorneys Jonathan Spivey, Jon Dudas, Courtenay Brinckerhoff, and Sharon Barner, along with IBM's David Kappos (now USPTO director)IP-Watch on Obama IP insiders [read post]
16 Aug 2012, 7:06 pm by Antoinette Konski
Read Foley & Lardner’s review and analysis here and Courtenay Brinckerhoff’s PharmaPatents post. [read post]